A Vaccine Construction against COVID-19-Associated Mucormycosis Contrived with Immunoinformatics-Based Scavenging of Potential Mucoralean Epitopes DOI Creative Commons
Muhammad Naveed, Urooj Ali, Mohmed Isaqali Karobari

et al.

Vaccines, Journal Year: 2022, Volume and Issue: 10(5), P. 664 - 664

Published: April 22, 2022

Mucormycosis is a group of infections, caused by multiple fungal species, which affect many human organs and lethal in immunocompromised patients. During the COVID-19 pandemic, current wave mucormycosis challenge to medical professionals as its effects are multiplied because severity infection. The variant concern, Omicron, has been linked fatal infections US Asia. Consequently, postdiagnostic treatments have rendered unsatisfactory. In this hour need, preinfection cure needed that may prevent individuals. This study proposes potential vaccine construct targeting mucor rhizopus species responsible for providing immunoprotection construct, with an antigenicity score 0.75 covering, on average, 92-98% world population, was designed using immunoinformatics approach. Molecular interactions major histocompatibility complex-1 (MHC-I), Toll-like receptors-2 (TLR2), glucose-regulated protein 78 (GRP78), scores -896.0, -948.4, -925.0, respectively, demonstrated bind immune receptors. It elicited strong predicted innate adaptive response form helper T (Th) cells, cytotoxic (TC) B natural killer (NK) macrophages. cloned pBR322 vector showed positive amplification, further solidifying stability potential. proposed holds promising approach first step towards antimucormycosis contribute minimizing burdens failures.

Language: Английский

Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India DOI Open Access
Awadhesh Kumar Singh, Ritu Singh, Shashank Joshi

et al.

Diabetes & Metabolic Syndrome Clinical Research & Reviews, Journal Year: 2021, Volume and Issue: 15(4), P. 102146 - 102146

Published: May 21, 2021

Language: Английский

Citations

1012
The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries DOI Creative Commons
Martin Hoenigl, Danila Seidel, Agostinho Carvalho

et al.

The Lancet Microbe, Journal Year: 2022, Volume and Issue: 3(7), P. e543 - e552

Published: Jan. 25, 2022

Citations

395
COVID‐19‐associated mucormycosis: An updated systematic review of literature DOI Open Access
Rimesh Pal, Birgurman Singh, Sanjay Kumar Bhadada

et al.

Mycoses, Journal Year: 2021, Volume and Issue: 64(12), P. 1452 - 1459

Published: June 16, 2021

In its wake, the COVID-19 pandemic has ushered in a surge number of cases mucormycosis. Most are temporally linked to COVID-19; hence, entity is described as COVID-19-associated mucormycosis (CAM). The present systematic review was undertaken provide an up-to-date summary hitherto available literature on CAM. PubMed, Scopus and Google Scholar databases were systematically searched using appropriate keywords till 14 May 2021, identify case reports/case series pertaining patients with COVID-19. Relevant data extracted included demographic characteristics, comorbidity profile, clinical category mucormycosis, glucocorticoid use, treatment offered patient outcome. We identified 30 series, pooling retrieved from 99 reported India (72%). majority male (78%) had diabetes mellitus (85%). A prior history 37% developing after initial recovery. median time interval between diagnosis first evidence infection or CAM 15 days. Glucocorticoid use 85% cases. Rhino-orbital most common (42%), followed by rhino-orbito-cerebral (24%). Pulmonary observed 10 (10%). mortality rate 34%; adjunct surgery, which 81% patients, associated better outcomes (p < .001). conclusion, emerging problem necessitating increased vigilance even those who have recovered. portends poor prognosis warrants early treatment.

Language: Английский

Citations

248
Epidemiology and Pathophysiology of COVID-19-Associated Mucormycosis: India Versus the Rest of the World DOI Creative Commons
Valliappan Muthu, Shivaprakash M. Rudramurthy, Arunaloke Chakrabarti

et al.

Mycopathologia, Journal Year: 2021, Volume and Issue: 186(6), P. 739 - 754

Published: Aug. 19, 2021

The coronavirus disease 2019 (COVID-19) pandemic has led to a concerning resurgence of mucormycosis. More than 47,000 cases mucormycosis were reported in three months from India. We update our systematic review on COVID-19-associated (CAM) till June 21st, 2021, comparing India and elsewhere. included individual patient details 275 CAM, which 233 42 the rest world. Diabetes mellitus was most common underlying risk factor for CAM other countries. fatality rate (36.5%) less globally (61.9%), probably due predominance rhino-orbital On multivariate analysis, we found that pulmonary or disseminated admission intensive care unit associated with increased mortality, while combination medical therapy improved survival. paucity suggests these either not diagnosed reported, further supported by trend search data Google engine. In this review, discuss factors explaining substantial rise CAM. also propose hypothetical model describing epidemiologic triad

Language: Английский

Citations

204
Mucormycosis: An opportunistic pathogen during COVID-19 DOI Open Access
Mahalaxmi Iyer, Kaavya Jayaramayya, Dhivya Venkatesan

et al.

Environmental Research, Journal Year: 2021, Volume and Issue: 201, P. 111643 - 111643

Published: July 6, 2021

Language: Английский

Citations

184
High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections DOI Open Access
Kinal Bhatt, Arjola Agolli, M. Patel

et al.

Discoveries, Journal Year: 2021, Volume and Issue: 9(1), P. e126 - e126

Published: March 31, 2021

Severe COVID-19 disease is associated with an increase in pro-inflammatory markers, such as IL-1, IL-6, and tumor necrosis alpha, less CD4 interferon-gamma expression, fewer CD8 cells, which the susceptibility to bacterial fungal infections. One opportunistic infection mucormycosis. Initially, it was debated whether a person taking immunosuppressants, corticosteroids, monoclonal antibodies will be at higher risk for or immunosuppresive state would cause more severe disease. However, immunosuppressants are currently continued unless patients greater of on high-dose corticosteroids therapy. As understood so far, may induce significant persistent lymphopenia, turn increases It also noted that 85% patients’ laboratory findings showed lymphopenia. This means have markedly lower absolute number T lymphocytes, CD4+T CD8+ cells and, since lymphocytes play major role maintaining immune homeostasis, highly susceptible co-infections. report intended raise awareness importance early detection treatment mucormycosis other diseases, candidiasis, SARS-CoV-2-associated pulmonary aspergillosis, pneumocystis pneumonia cryptococcal disease, patients, reduce mortality.

Language: Английский

Citations

170
Mucormycosis and COVID‐19: An epidemic within a pandemic in India DOI Open Access

Lav Selarka,

Suktara Sharma, Dinesh Kumar Saini

et al.

Mycoses, Journal Year: 2021, Volume and Issue: 64(10), P. 1253 - 1260

Published: July 13, 2021

Coronavirus disease (COVID-19) causes an immunosuppressed state and increases risk of secondary infections like mucormycosis. We evaluated clinical features, predisposing factors, diagnosis outcomes for mucormycosis among patients with COVID-19 infection. This prospective, observational, multi-centre study included 47 consecutive mucormycosis, diagnosed during their course illness, between January 3 March 27, 2021. Data regarding demography, underlying medical conditions, illness treatment were collected. Clinical presentations imaging biochemical characteristics outcome recorded. Of the 2567 admitted to tertiary centres, (1.8%) Mean age was 55 ± 12.8years, majority suffered from diabetes mellitus (n = 36, 76.6%). Most not vaccinated 31, 66.0%) 43, 91.5%) had developed moderate-to-severe pneumonia, while 20 (42.6%) required invasive ventilation. All received corticosteroids broad-spectrum antibiotics most 37, 78.7%) at least one anti-viral medication. time elapsed 12.1 4.6days. Eleven (23.4%) subjects succumbed disease, mostly 8, 72.7%) within 7 days diagnosis. Among who died, 10 (90.9%) pre-existing mellitus, only 2 (18.2%) just vaccine dose all requiring oxygen supplementation mechanical Mucormycosis can occur patients, especially poor glycaemic control, widespread injudicious use antibiotics, Owing high mortality, index suspicion is ensure timely appropriate in high-risk populations.

Language: Английский

Citations

168
COVID-19 and mucormycosis superinfection: the perfect storm DOI Creative Commons
Jaffar A. Al‐Tawfiq, Saad Alhumaid, Abeer N. Alshukairi

et al.

Infection, Journal Year: 2021, Volume and Issue: 49(5), P. 833 - 853

Published: July 24, 2021

The recent emergence of the Coronavirus Disease (COVID-19) disease had been associated with reports fungal infections such as aspergillosis and mucormycosis especially among critically ill patients treated steroids. surge in cases COVID-19 India during second wave pandemic increased reporting invasive post COVID-19. There are multiple case series describing In this review, we included most reported case-series describe clinical features outcome. Many were eported from India, who recovered patients. commonly infection sites rhino-orbital/rhino-cerebral mucormycosis. Those diabetic corticosteroids therapy for controlling severity COVID-19, leading to a higher fatality complicating scenario. triad severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), corticosteroid use uncontrolled diabetes mellitus have evident significant increase incidence angioinvasive maxillofacial addition, presence spores other factors might play role well. With ongoing increasing number infected SARS-CoV-2, it is important develop risk-based approach at risk based on epidemiological burden mucormycosis, prevalence mellitus, immune modulating agents including combined immunosuppressive cancer transplants.

Language: Английский

Citations

156
Pulmonary aspergillosis and mucormycosis in a patient with COVID-19 DOI Creative Commons
Andre K. Johnson,

Zeron Ghazarian,

Kristina D. Cendrowski

et al.

Medical Mycology Case Reports, Journal Year: 2021, Volume and Issue: 32, P. 64 - 67

Published: April 7, 2021

Invasive pulmonary mucormycosis and aspergillosis are rare, life-threatening fungal infections. Most documented cases have been reported in patients with diabetes mellitus, neutropenia, or treatment corticosteroids. Both infections recognized as secondary complications of COVID-19, especially among critically ill patients. We report the first case combined probable possible a male COVID-19 ICU.

Language: Английский

Citations

126
COVID-19-associated mucormycosis: Case report and systematic review DOI Open Access
Ahmet Dilek, Reşat Özaras, Şevket Özkaya

et al.

Travel Medicine and Infectious Disease, Journal Year: 2021, Volume and Issue: 44, P. 102148 - 102148

Published: Aug. 25, 2021

Language: Английский

Citations

85